About SpliSense
SpliSense is a company based in Jerusalem (Israel) founded in 2016. SpliSense has raised $41.5 million across 3 funding rounds from investors including Orbimed, Cystic Fibrosis Foundation and Israel Biotech Fund. SpliSense offers products and services including SPL84, SPL5AC, SPL5B, and SPL23. SpliSense operates in a competitive market with competitors including Orgenesis, Ori Biotech, MaSTherCell, Cognate Bioservices and eXmoor, among others.
- Headquarter Jerusalem, Israel
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$41.5 M (USD)
in 3 rounds
-
Latest Funding Round
$13 M (USD), Series B
Jun 16, 2026
-
Investors
Orbimed
& 3 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of SpliSense
SpliSense offers a comprehensive portfolio of products and services, including SPL84, SPL5AC, SPL5B, and SPL23.
Targets cystic fibrosis using ASOs to modify protein function.
Addresses muco-obstructive diseases through RNA-based interventions.
Focuses on pulmonary conditions via Antisense Oligonucleotides.
Develops treatments for additional pulmonary disease opportunities.
People of SpliSense
Unlock access to complete
Unlock access to complete
Funding Insights of SpliSense
SpliSense has successfully raised a total of $41.5M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $13 million completed in June 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in SpliSense
SpliSense has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Orbimed, Cystic Fibrosis Foundation and Israel Biotech Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Israeli life science ventures are funded by Integra Holdings.
|
Locked | Locked | Locked |
Investor details for SpliSense
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by SpliSense
Investment portfolio details for SpliSense
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - SpliSense
Detailed financials for SpliSense
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Splisense Comparisons
Peer comparison for SpliSense
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of SpliSense
SpliSense operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Orgenesis, Ori Biotech, MaSTherCell, Cognate Bioservices and eXmoor, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Cell and gene therapies for multiple disorders are developed.
|
|
| Locked | Locked | Locked |
Software development services are provided for the biopharma sector.
|
|
| Locked | Locked | Locked |
Services for cell therapy development and manufacturing are provided.
|
|
| Locked | Locked | Locked |
Development and manufacturing services for cell-based therapies are provided.
|
|
| Locked | Locked | Locked |
Cell and gene therapeutic services are provided to biopharmaceutical firms.
|
Detailed competitors of SpliSense
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Splisense
Complete news archive for SpliSense
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SpliSense
SpliSense was founded in 2016 and raised its 1st funding round 1 year after it was founded.
SpliSense is headquartered in Jerusalem, Israel. It is registered at Jerusalem, Jerusalem District, Israel.
SpliSense is a funded company, having raised a total of $41.5M across 3 funding rounds to date.
SpliSense was founded in 2016 and is headquartered in Jerusalem, Israel. The companys domain is registered as splisense.com. Limited information is available concerning its industry sector, core operations, or specific services. Details on business activities and geographical scope beyond the founding location are not provided in current records. Further data would be required for a comprehensive overview.
SpliSense's top competitors include Ori Biotech, MaSTherCell and OBiO Technology.
SpliSense offers SPL84, SPL5AC, SPL5B, and SPL23.
SpliSense has 4 investors. Key investors include Orbimed, Cystic Fibrosis Foundation, Israel Biotech Fund, and Integra Holdings.